A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Benjamin Izar, William Sharfman, F. Stephen Hodi, Donald Lawrence, Keith T. Flaherty, Ravi Amaravadi, Kevin B. Kim, Igor Puzanov, Jeffrey Sosman, Reinhard Dummer, Simone M. Goldinger, Lyhping Lam, Shefali Kakar, Zhongwen Tang, Oliver Krieter, David F. Mcdermott, Michael B. Atkins*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status'. Together they form a unique fingerprint.

Medicine & Life Sciences